Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model

Diabetologia

Volumn 56, Issue 8, 2013, Pages 1752-1760

  Omar, B A ^a   Vikman, J ^a   Winzell, M S ^a,b   Voss, U ^c   Ekblad, E ^c   Foley, J E ^d   Ahren B ^a  

^a LUND UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Beta cell function; DPP 4 inhibitor; Glucose tolerance; High fat diet; Longevity; Mouse islets; Peri insulitis

Indexed keywords

CD3 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; GLUCOSE; INSULIN; VILDAGLIPTIN;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD3+ T LYMPHOCYTE; CELL FUNCTION; CELL SIZE; CELL SURVIVAL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; FEMALE; GLUCOSE TOLERANCE; INSULIN RELEASE; INSULITIS; LIPID DIET; MOUSE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREATITIS; PRIORITY JOURNAL; SURVIVAL TIME;

ADAMANTANE; ANIMALS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; IMMUNOHISTOCHEMISTRY; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; NITRILES; OBESITY; PYRROLIDINES;

EID: 84879914429     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2927-8     Document Type: Article

References (37)

1. Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC (2006) Relationship between beta cell mass and fasting blood glucose concentration in humans. Diabetes Care 29:717-718
2. Ahren B (2011) The future of incretin-based therapy: novel avenues - novel targets. Diabetes Obes Metab 13(Suppl 1):158-166
3. Mu J, Woods J, Zhou YP et al (2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695-1704
4. Duttaroy A, Voelker F, Merriam K et al (2011) The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol 650:703-707
5. Takeda Y, Fujita Y, Honjo J et al (2012) Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 55:404-412
6. Furuta Y, Horiguchi M, Sugaru E et al (2010) Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta cell damage in diabetic mice. Diabetes Obes Metab 12:421-430
7. Mu J, Petrov A, Eiermann GJ et al (2009) Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 623:148-154
8. Zhang X, Wang Z, Huang Y, Wang J (2011) Effects of chronic administration of alogliptin on the development of diabetes and beta cell function in high fat diet/streptozotocin diabetic mice. Diabetes Obes Metab 13:337-347
9. Muhlhausler BS (2009) Nutritional models of type 2 diabetes mellitus. Meth Mol Biol 560:19-36
10. Koopman RJ, Mainous AG 3rd, Diaz VA, Geesey ME (2005) Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med 3:60-63
11. Ahren J, Ahren B, Wierup N (2010) Increased beta cell volume in mice fed a high-fat diet: a dynamic study over 12 months. Islets 2:353-356
12. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta cell deficit and increased beta cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110
13. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE (2011) Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 13:775-783
14. Myrsen U, Keymeulen B, Pipeleers DG, Sundler F (1996) Beta cells are important for islet innervation: evidence from purified rat islet-cell grafts. Diabetologia 39:54-59
15. Aoki CA, Borchers AT, Ridgway WM, Keen CL, Ansari AA, Gershwin ME (2005) NOD mice and autoimmunity. Autoimmun Rev 4:373-379
16. Henry RR (1998) Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention. Am J Med 105:20S-26S
17. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R (2003) The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes 52:1475-1484
18. Blackwell BN, Bucci TJ, Hart RW, Turturro A (1995) Longevity, body weight, and neoplasia in ad libitum-fed and diet-restricted C57BL6 mice fed NIH-31 open formula diet. Toxicol Pathol 23:570-582
19. Miura K, Kitahara Y, Yamagishi S (2010) Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats. Horm Metab Res 42:731-735
20. Inaba W, Mizukami H, Kamata K, Takahashi K, Tsuboi K, Yagihashi S (2012) Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats. Eur J Pharmacol 691:297-306
21. Reimer MK, Holst JJ, Ahren B (2002) Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146:717-727
22. Ahren B, Foley JE (2008) The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl (159):8-14
23. Foley JE, Bunck MC, Moller-Goede DL et al (2011) Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 54:1985-1991
24. Cnop M, Hughes SJ, Igoillo-Esteve M et al (2010) The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia 53:321-330
25. Rankin MM, Kushner JA (2009) Adaptive beta cell proliferation is severely restricted with advanced age. Diabetes 58:1365-1372
26. Tschen SI, Dhawan S, Gurlo T, Bhushan A (2009) Age-dependent decline in beta cell proliferation restricts the capacity of beta cell regeneration in mice. Diabetes 58:1312-1320
27. Bonner-Weir S, Trent DF, Weir GC (1983) Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 71:1544-1553
28. Rankin MM, King KB, Kim JJ, Tu JX, Li C, Kushner JA (2012) New B cells are not generated by prolonged administration of incretin-based therapies (exendin-4 or sitagliptin) in adult mouse pancreas. Diabetes 61:LB34
29. Giarratana N, Penna G, Adorini L (2007) Animal models of spontaneous autoimmune disease: type 1 diabetes in the nonobese diabetic mouse. Meth Mol Biol 380:285-311
30. Dobrian AD, Ma Q, Lindsay JW et al (2011) Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab 300:E410-E421
31. Ferreira L, Teixeira-de-Lemos E, Pinto F et al (2010) Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediat Inflamm 2010:592760
32. Kim SJ, Nian C, Doudet DJ, McIntosh CH (2009) Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T cell modulation. Diabetes 58:641-651
33. Tian L, Gao J, Hao J et al (2010) Reversal of new-onset diabetes through modulating inflammation and stimulating beta cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 151:3049-3060
34. Morimoto C, Schlossman SF (1998) The structure and function of CD26 in the T cell immune response. Immunol Rev 161:55-70
35. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408:239-247
36. Leibowitz G, Bachar E, Shaked M et al (2010) Glucose regulation of beta cell stress in type 2 diabetes. Diabetes Obes Metab 12(Suppl 2):66-75
37. Rizzo MR, Barbieri M, Marfella R, Paolisso G (2012) Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 35:2076-2082